首页> 美国卫生研究院文献>other >Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes
【2h】

Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes

机译:放线菌属生产拉莫普林和拉莫普林类似物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ramoplanin is a glycolipodepsipeptide antibiotic obtained from fermentation of Actinoplanes sp. ATCC 33076 that exhibits activity against clinically important multi-drug-resistant, Gram-positive pathogens including vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-intermediate resistant Clostridium difficile. It disrupts bacterial cell wall through a unique mechanism of action by sequestering the peptidoglycan intermediate Lipid II and therefore does not show cross-resistance with other antibiotics. However, while demonstrating excellent antimicrobial activity in systemic use in animal models of infection, ramoplanin presents low local tolerability when injected intravenously. As a consequence of this limitation, new derivatives are desirable to overcome this issue. During a natural product screening program developed to discover compounds that disrupt bacterial cell wall synthesis by inhibiting peptidoglycan transglycosylation through binding to the intermediate Lipid II, 49 actinomycete strains were identified by HR-LCMS as producers of ramoplanin-related compounds. The producing strains were isolated from environmental samples collected worldwide comprising both tropical and temperate areas. To assess the diversity of this microbial population, the 49 isolates were initially identified to the genus level on the basis of their micromorphology, and 16S sequencing confirmed the initial identification of the strains. These analyses resulted in the identification of members of genus Streptomyces, as well as representatives of the families Micromonosporaceae, Nocardiaceae, Thermomonosporaceae, and Pseudonocardiaceae, suggesting that the production of ramoplanins is relatively widespread among Actinomycetes. In addition, all of these isolates were tested against a panel of Gram-positive and Gram-negative bacteria, filamentous fungi, and yeast in order to further characterize their antimicrobial properties. This work describes the diversity of actinomycete strains that produced ramoplanin-related compounds, and the analysis of the antimicrobial activity exhibited by these isolates. Our results strongly suggest the presence of new ramoplanin-analogs among these actinomycete producers.
机译:Ramoplanin是一种糖脂肽肽抗生素,是从Actinoplanes sp。发酵获得的。 ATCC 33076表现出对临床上重要的多重耐药革兰氏阳性病原体的活性,这些病原体包括耐万古霉素的肠球菌(VRE),耐甲氧西林的金黄色葡萄球菌(MRSA)和耐万古霉素的艰难梭菌。它通过隔离肽聚糖中间体脂质II来通过独特的作用机制破坏细菌细胞壁,因此与其他抗生素没有交叉耐药性。但是,尽管在感染动物模型的全身使用中显示出优异的抗菌活性,但雷莫拉宁在静脉内注射时表现出较低的局部耐受性。由于这种限制,需要新的衍生物来克服这个问题。在开发的天然产物筛选程序中,发现了通过与中间体脂质II结合而通过抑制肽聚糖转糖基化来破坏细菌细胞壁合成的化合物,HR-LCMS确定了49种放线菌菌株是与雷莫拉菌素相关的化合物的生产者。从全球包括热带和温带地区收集的环境样品中分离出生产菌株。为了评估该微生物种群的多样性,首先根据其微观形态将49个分离株鉴定到属水平,并且16S测序确认了菌株的初步鉴定。这些分析导致鉴定了链霉菌属的成员以及微单孢菌科,诺卡菌科,热单孢菌科和假心卡菌科的代表,这表明在放线菌中雷莫拉菌素的生产相对广泛。此外,针对所有革兰氏阳性和革兰氏阴性细菌,丝状真菌和酵母,对所有这些分离物进行了测试,以进一步表征其抗菌性能。这项工作描述了产生雷莫拉宁相关化合物的放线菌菌株的多样性,以及对这些分离物表现出的抗菌活性的分析。我们的结果强烈暗示在这些放线菌生产者中存在新的雷莫拉宁类似物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号